Compare OC & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OC | IMVT |
|---|---|---|
| Founded | 1938 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 8.5B |
| IPO Year | 2006 | 2019 |
| Metric | OC | IMVT |
|---|---|---|
| Price | $122.67 | $30.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 17 |
| Target Price | ★ $146.31 | $48.88 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $97.53 | $21.43 |
| 52 Week High | $159.91 | $45.42 |
| Indicator | OC | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 50.53 |
| Support Level | $116.32 | $30.24 |
| Resistance Level | $130.24 | $34.60 |
| Average True Range (ATR) | 5.46 | 1.21 |
| MACD | 1.58 | 0.46 |
| Stochastic Oscillator | 68.95 | 97.72 |
Owens-Corning Inc is a building products company that offers roofing products and systems, insulation products (hermal and acoustical batts, loose fill insulation, spray foam insulation, wet use chopped strand, etc.), and doors and door systems. The company's reportable segments are: Roofing, Insulation, and Doors. Maximum revenue is generated from the Roofing segment, which manufactures and sells residential roofing shingles, oxidized asphalt materials, roofing components, and composite lumber mainly used in residential construction. This segment also manufactures and sells glass mat and specialty veil materials used in building and construction applications. Geographically, the company generates maximum revenue from the United States, followed by Europe, Asia-Pacific, and other markets.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.